Literature DB >> 29356713

Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty.

W Glenn McCluggage1.   

Abstract

Accurate staging of cancers is an important determinant of prognosis and guides optimal patient treatment. Although the International Collaboration on Cancer Reporting recommends that endometrial cancers (including carcinosarcomas) are pathologically staged using the International Federation of Gynecology and Obstetrics (FIGO) 2009 system, in many areas TNM [American Joint Committee on Cancer (AJCC) or Union for International Cancer Control (UICC)] staging is used or even mandated; these latter systems are based on FIGO 2009. In this review, areas of difficulty in the pathologic staging of endometrial carcinomas are covered with practical advice for the reporting pathologist. These include issues regarding the assessment of the depth of myometrial involvement (which may be rendered difficult due to a variety of factors), tumor involvement of adenomyosis, and assessment of cervical and uterine serosal involvement. Although not included in the FIGO staging system, the issue of lymphovascular space invasion (LVSI) is covered as this is of prognostic importance and there are multiple problems in the pathologic assessment of this. One important point is that tumors should not be upstaged based on the presence of LVSI alone without tissue involvement; for example, the presence of LVSI in the outer half of the myometrium or in cervical or adnexal vessels in a carcinoma with myoinvasion confined to the inner half of the myometrium is still FIGO stage IA. The issue of simultaneously occurring tumors of the endometrium and adnexa is also covered with advice on how to distinguish between synchronous independent and metastatic neoplasms of both endometrioid and nonendometrioid types. Recent molecular evidence showing that simultaneously occurring endometrioid carcinomas of the endometrium and ovary are clonal and thus probably represent metastatic disease from the endometrium to the ovary rather than synchronous independent neoplasms, as is widely assumed, is discussed.

Entities:  

Mesh:

Year:  2018        PMID: 29356713     DOI: 10.1097/PAP.0000000000000182

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  5 in total

1.  Associations Between Intraluminal Tumor Cell Involvement in Serially Examined Fallopian Tubes and Endometrial Carcinoma Characteristics and Outcomes.

Authors:  Monica Rodriquez; Ashley S Felix; Mary Anne Brett; Goli Samimi; Máire A Duggan
Journal:  Int J Gynecol Pathol       Date:  2021-08-11       Impact factor: 3.326

2.  Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.

Authors:  Gitte Ørtoft; Lisa Lausten-Thomsen; Claus Høgdall; Estrid S Hansen; Margit Dueholm
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

3.  A Lymph Node Count-Based AJCC Staging System Facilitates a More Accurate Prediction of the Prognosis of Patients With Endometrial Cancer.

Authors:  Xinlong Huo; Shufang Wang
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

4.  Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes.

Authors:  Aitor Rodríguez-Martínez; Carla Trapero; August Vidal; Josep Maria Piulats; Inmaculada Gómez de Aranda; Jean Sévigny; Maria Eulàlia Fernández-Montolí; Jordi Ponce; Xavier Matias-Guiu; Mireia Martín-Satué
Journal:  J Pers Med       Date:  2021-04-22

Review 5.  Radiology-pathology correlation of endometrial carcinoma assessment on magnetic resonance imaging.

Authors:  Eveline Dokter; Lyndal Anderson; Soo-Min Cho; Violette Cohen-Hallaleh; Kim May Lam; Samir A Saidi; Yu Xuan Kitzing
Journal:  Insights Imaging       Date:  2022-04-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.